Diovan Articles
Overview of Novartis' patent losses from GlobalData
11 October 2012
Novartis cuts jobs, takes $1.22 billion charges
13 January 2012
Actavis debuts generic Diovan in major European markets
20 November 2011
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal
27 January 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Batch of Japanese drug approvals, including for Taiho, Daiichi Sankyo and three for Novartis
20 January 2010
Fixed-dose combo of telmisartan/amlodipine “will become clinical gold standard for hypertension” in 2013
8 January 2010
Novartis to buy Corthera for $120 million, plus up to $500 million on success of ADHF drug relaxin
23 December 2009
Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told
9 December 2009
Malaysian govt encouraging biotech sector of pharma market
22 October 2009
Good news for Novartis’s MS drug fingolimod
1 October 2009
Fixed-dose antihypertensive cannot stem tide of patent expiries
4 September 2009
UCB extends German cardio/diabetes deal with Novartis
29 August 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Afinitor cleared in USA for advanced RCC
1 April 2009
Four Novartis drugs and B-MS
9 March 2009
Expanded EU label for Novartis' Diovan
9 March 2009
Novartis speeds R&D ahead of Diovan loss
12 January 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
Novartis lines up aliskiren combos and cancer drugs to deal with Diovan's 2012 patent loss
24 November 2008
Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
27 October 2008
Novartis profit up 32% in 3rd qtr
27 October 2008
Tekturna sales harmed by Novartis shakeup?
23 June 2008
Teva gains tentative approval for generic Diovan
23 June 2008
Novartis' Diovan boosts artery elasticity
16 June 2008
Good results for Novartis' Exforge
2 June 2008
Ipsen reports 8.4% sales growth in 1st qtr
12 May 2008
ARB switching strategy may not result in long-term savings within a five-year model, says Merck & Co
12 May 2008
US physician survey finds big differences in Rx patterns between cardiologists and PCPs
4 February 2008
Novartis to boost Spanish Diovan production
28 January 2008
Raft of pending patent expiries threaten cardiovascular blockbusters
10 December 2007
Ranbaxy's valsartan gets tentative FDA OK
5 November 2007
Novartis to invest in Singapore MAb plant
5 November 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
Novartis to invest 300M CHFs in drug plant
3 September 2007
Novartis' Diovan wins US pediatric exclusivity
20 August 2007
Nuvelo begins R&D collaboration with Kirin Brewery
25 June 2007
Exforge cuts mean bp 20mmHg in Ph III trial
28 May 2007
Diovan plus standard therapy cuts CV events
7 May 2007
Novartis' 1st-qtr 2007 profit up 11% to $2.17B on strong sales of cancer drugs and Diovan
30 April 2007
Stock Commentary - Europe - week to April 9
16 April 2007
Novartis' Tekturna and Diovan work in synergy
2 April 2007
Novartis and Speedel
12 March 2007
Exforge shows safety and efficacy in bp study
26 February 2007
Ipsen's 2006 sales grow 6.8% to 861.7M euros
12 February 2007
Novartis and Mochida to co-promote Diovan
29 January 2007
Novartis' Exforge cleared by EU regulator
29 January 2007
Diovan, Glivec and generics drive Novartis growth in 2006
22 January 2007
Novartis' Exforge approved by FDA
8 January 2007
Diovan reduces level of proteinuria in diabetics
20 November 2006
Novartis sees 16% sales jump in first three qtrs of 2006 beating consensus estimates
30 October 2006
Aegate joins forces with Belgian pharmacy association
23 October 2006
Valsartan performs well in Japanese study
18 September 2006
BI's Micardis lowers BP more than other ARBs
26 June 2006
FDA OKs higher dose of Novartis' Diovan
8 May 2006
Genesis invests in China's Liang Fang
27 March 2006
Novartis seeks EU approval for Lucentis
13 March 2006
Novartis sees strong performance with record results in 2005
30 January 2006
USA
22 August 2005
New data shows CV benefits for Novartis' Diovan
4 July 2005
EU appro for Novartis' Diovan in heart failure
20 June 2005
Novartis' Diovan cuts diabetes risk
30 May 2005
Novartis' Diovan gets EU nod for heart attack
16 May 2005
France's Ipsen sees 8.6% sales growth
16 May 2005
Novartis' Diovan gets UK OK for new use
1 November 2004
Novartis nine-month net income leaps 21%
25 October 2004
Novartis debuts Co-Diovan in UK
13 September 2004
Novartis to invest $180M in Singapore drug production plant
23 August 2004
Tokyo pharma stocks - week to June 21
28 June 2004
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
